Modern aspects of detection and monitoring of preclinical stages of type 1 diabetes mellitus in children

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Type 1 diabetes mellitus (DM1) is one of the most common endocrine diseases in children. DM1 develops as a result of the interaction of a predisposing genetic background and epigenetic factors. Identification of patients at risk of developing DM1 is the key to developing strategies to prevent the development of the disease. Autoantibody-based screening provides information on the current DM1 stage, the time before the risk of developing stage 3 DM1. The introduction of screening for DM1 has potential benefits, namely, a decrease in the development of diabetic ketoacidosis, a decrease in stress on the part of parents and children when making a diagnosis, and the possibility of better psychological adaptation.

全文:

受限制的访问

作者简介

Tatyana Varlamova

Petrozavodsk State University

编辑信件的主要联系方式.
Email: varlamova@sampo.ru
ORCID iD: 0000-0001-5617-8893
Scopus 作者 ID: 58819203900

Cand. Sci. (Med.), Associate Professor, Medical Institute named after prof. A.P. Zilber

俄罗斯联邦, Petrozavodsk

N. Vezikova

Petrozavodsk State University

Email: varlamova@sampo.ru
ORCID iD: 0000-0002-8901-3363
Scopus 作者 ID: 6505871479
俄罗斯联邦, Petrozavodsk

参考

  1. Ogle G.D., James S., Dabelea D., et al. Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition. Diab Res Clin Pract. 2022;183:109083. doi: 10.1016/j.diabres.2021.109083.
  2. Knip M., Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(7):a007690. doi: 10.1101/cshperspect.a007690.
  3. Knip M. Type 1 diabetes in Finland: past, present, and future. Lancet. Diab Endocrinol. 2021;9(5):259–60. doi: 10.1016/S2213-8587(21)00074-7.
  4. Лаптев Д.Н., Безлепкина О.В., Шешко Е.Л. и др. Основные эпидемиологические показатели сахарного диабета 1 типа у детей в Российской Федерации за 2014–2023 гг. Проблемы эндокринологии. 2024;70(5):76–83. [Laptev D.N., Bezlepkin O.V., Sheshko E.L., et al. The main epidemiological indicators of type 1 diabetes mellitus in children in the Russian Federation for 2014–2023. Problems of Endocrinology. 2024;70(5):76–83. (In Russ.)]. doi: 10.14341/probl13515.
  5. Pociot F., Lernmark A. Genetic risk factors for type 1 diabetes. Lancet. 2016;387:2331–9. doi: 10.1016/S0140-6736(16)30582-7.
  6. Simmons K.M., Sims E.K. Screening and Prevention of Type 1 Diabetes: Where Are We? J Clin Endocrinol Metab. 2023;108:3067–79. doi: 10.1210/clinem/dgad328.
  7. Кураева Т.Л., Титович Е.В., Прокофьев С.А. и др. Генетические и иммунологические технологии определения риска развития сахарного диабета 1 типа. Перспективы предупреждения болезни. Пособие для врачей. Под ред. акад. РАН и РАМН И.И. Дедова. М., 2011. 24 с. Kuraeva T.L., Titovich E.V., Prokofiev S.A., et al. Genetic and immunological technologies for determining the risk of developing type 1 diabetes mellitus. Prospects for disease prevention. A manual for doctors. Ed. by Academician of the Russian Academy of Sciences and Russian Academy of Medical Sciences I.I. Dedov. Moscow, 2011. 24 p. (In Russ.)].
  8. Morran M.P., Omenn G.S., Pietropaolo M. Immunology and genetics of type 1 diabetes. Mt Sinai J Med. 2008;75(4):314–27. doi: 10.1002/msj.20052.
  9. Peet A., Kool P., Ilonen J., et al for the DIABIMMUNE Study Group. Birth weight in newborn infants with different diabetes-associated HLA genotypes in three neighbouring countries: Finland, Estonia and Russian Karelia. Diab Metab Res Rev. 2012;28:455–61. doi: 10.1002/dmrr.2303.
  10. Primavera M., Giannini C., Chiarelli F. Prediction and prevention of type 1 diabetes. Front Endocrinol (lausanne). Front Endocrinol (Lausanne). 2020;11:248. doi: 10.3389/fendo.2020.00248.
  11. Ziegler A.G., Rewers M., Simell O., et al. Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children. JAMA. 2013;309(23):2473–9. doi: 10.1001/jama.2013.6285.
  12. Insel R.A., Dunne J.L., Atkinson M.A., et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diab Care. 2015;38(10):1964–74. doi: 10.2337/dc15-1419.
  13. Parkkola A., Härkönen Т., et al. Extended Family History of Type 1 Diabetes and Phenotype and Genotype of Newly Diagnosed Children. Diab Care. 2013;36(2):348–54. doi: 10.2337/dc12-0445.
  14. Maahs D.M., Nancy A. West et al. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481–97. doi: 10.1016/j.ecl.2010.05.011.
  15. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diab Care. 2015;38(6):989–96.
  16. Glaser N., Fritsch M., Priyambada L., et al. ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diab. 2022;23(7):835–56. doi: 10.1111/pedi.13406.
  17. Gagnum V., Stene L.C., et al. Causes of death in childhood-onset Type 1 diabetes: long-term follow-up. Diab Med. 2017;34(1):56–63. doi: 10.1111/dme.13114.
  18. Ramphul K., Joynauth J. An Update on the Incidence and Burden of Diabetic Ketoacidosis in the U.S Diab Care. 2020;43(12):e196–7. doi: 10.2337/dc20-1258.
  19. Wasag D.R., Gregory J.W., Dayan C., Harvey J.N., on behalf of the Brecon Group. Excess all-cause mortality before age 30 in childhood onset type 1 diabetes: data from the Brecon Group Cohort in Wales. Arch Dis Child. 2018;103:44–8. doi: 10.1136/archdischild-2016-312581.
  20. Lawrence S.E., Cummings E.A., et al. Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. J Pediatr. 2005;146:688–92. doi: 10.1016/j.jpeds.2004.12.041.
  21. Edge J.A., Jakes R.W., et al. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetol. 2006;49:2002–9. doi: 10.1007/s00125-006-0363-8.
  22. Curtis J.R., To T., Muirhead S., Cummings E., et al. Recent trends in hospitalization for diabetic ketoacidosis in Ontario children. Diab Care. 2002;25(9):1591–6. doi: 10.2337/diacare.25.9.1591.
  23. Poovazhagi V. World Risk factors for mortality in children with diabetic keto acidosis from developing countries. J Diab. 2014;5(6):932–8. doi: 10.4239/wjd.v5.i6.932.
  24. Myers S.R., Nicole S. Glaser et al. Frequency and Risk Factors of Acute Kidney Injury During Diabetic Ketoacidosis in Children and Association With Neurocognitive Outcomes. JAMA. Netw Open. 2020;3(12):e2025481.2020.25481. doi: 10.1001/jamanetworkopen.2020.25481.
  25. Hursh B.E., Rebecca R., al. Acute Kidney Injury in Children With Type 1 Diabetes Hospitalized for Diabetic Ketoacidosis. JAMA. Pediatr. 2017;171(5):e170020. doi: 10.1001/jamapediatrics.2017.002.
  26. Glaser N.S., Marcin J.P., et al. Correlation of clinical and biochemical findings with diabetic ketoacidosis-related cerebral edema in children using magnetic resonance diffusion-weighted imaging. J Pediatr. 2008;153(4):541–6. doi: 10.1016/j.jpeds.2008.04.048.
  27. de Wit M., Gajewska K.A., Goethals E.R., et al. ISPAD clinical practice consensus guidelines 2022: psychological care of children, adolescents and young adults with diabetes. Pediatr Diab. 2022;23:1373–89. doi: 10.1111/pedi.13428.
  28. Rechenberg K., Whittemore R., Grey M. Anxiety in youth with type 1 diabetes. J Pediatr Nurs. 2017;32:64–71. doi: 10.1016/j.pedn.2016.08.007.
  29. Smith L.B. Liu X., et al. Family adjustment to diabetes diagnosis in children: can participation in a study on type 1 diabetes genetic risk be helpful? Pediatr Diab. 2018;19:1025–33. doi: 10.1111/pedi.12674.
  30. Whittemore R., Jaser S., Chao A., et al. Psychological experience of parents of children with type 1 diabetes. Diab Educ. 2012;38:562–79. doi: 10.1177/0145721712445216.
  31. Bassi G., Mancinelli E., Di Riso D., Salcuni S. Parental stress, anxiety and depression symptoms associated with self-efficacy in paediatric type 1 diabetes: a literature review. Int J Environ Res Public Health. 2021;18:152. doi: 10.3390/ijerph18010152.
  32. Rawshani A., et al. Excess mortality andcardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477–86. doi: 10.1016/S0140-6736(18)31506-X.
  33. Gaudieri P.A., Chen R., Greer T.F., Holmes C.S. Cognitive function in childrenwith type 1 diabetes: a meta-analysis. Diab Care. 2008;31(9):1892–7. doi: 10.2337/dc07-2132.
  34. Steffes M.W., et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diab Care. 2003;26(3):832–6. doi: 10.2337/diacare.26.3.832.
  35. Jeyam A., et al. Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and MicrovascularComplications. Diab Care. 2021;44(2):390–8. doi: 10.2337/dc20-0567.
  36. Hummel S., et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milderdiabetes at clinical manifestation. Diabetol. 2023;66(9):1633–42. doi: 10.1007/s00125-023-05953-0.
  37. Sims E.K., et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 2022;71(4):610–23. doi: 10.2337/dbi20-0054.
  38. Ziegler A.G., Kick K., Bonifacio E., et al. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA. 2020;323(4):339–51. doi: 10.1001/jama.2019.21565.
  39. Larsson H.E., Vehik K., et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diab Care. 2011;34(11):2347–52. doi: 10.2337/dc11-1026.
  40. Barker J.M., et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diab Care. 2004; 27(6):1399–404. doi: 10.2337/diacare.27.6.1399.
  41. Besser R.E.J., Ng S.M., Gregory J.W., et al. General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch Dis Childhood. 2022;107:790–5. doi: 10.1136/archdischild-2021-321864.
  42. Haller M.J., et al. Karger 2024. ISPAD. Clinical Practice Consensus Guidelines. 2024. doi: 10.1159/000543035.
  43. Phillip M., Achenbach P., Addala A., et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetol. 2024;67:1731–59. doi: 10.1007/s00125-024-06205-5.

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure 1. Percentage of admissions of children with newly diagnosed type 1 diabetes with diabetic ketoacidosis in the Republic of Karelia (2020-2024)

下载 (62KB)
索引源数据
3. Figure 2. Routing scheme for children and adolescents at risk for type 1 diabetes with an autoimmune reaction with the production of autoantibodies (AA) in the Republic of Karelia

下载 (154KB)
索引源数据

版权所有 © Bionika Media, 2025